Sandeep Gurram
@SandeepGurramMD
Followers
286
Following
376
Media
6
Statuses
75
MD, Urology Oncology Fellow @theNCI | Interests: Trials in Bladder and Kidney Cancer | Views are my own
Joined December 2019
Excited to share our work performed at @theNCI addressing needs of rare hereditary kidney cancer through bench to bedside work Bevacizumab + erlotinib for #HLRCC assoc RCC 📍Response rate 72% 📍mPFS 21.1 mo Thanks to the patients who supported the study! https://t.co/lJhRgR0ejb
2
19
85
🎉We are very happy to see that our study is selected as semifinalist for AuntMinnnie’s scientific paper of the year 👍Congratulations to @davidgelikman @DrSHarmon @eniscy and our amazing team #prostatecancer #teamscience #cancerresearch
AJR is honored to have two papers selected as semifinalists for AuntMinnie's Scientific Paper of the Year. We are proud to publish research of this caliber and extend our congratulations to the authors.
1
8
24
(4/4) New promising activity has been noted with the addition of immunotherapy/checkpoint inhibitors to TKIs in retrospective series Current prospective clinical trials at the NCI and other sites are ongoing and we await their results 👇Info below 🔗 https://t.co/tHAyJl3QGa
0
0
4
(3/4) Prior TKI regimens had disappointing efficacy with median survival from 16-21 mo However, by utilizing bevacizumab (VEGFA inhibitor) and erlotinib (anti-EGFR TKI), the vulnerabilities in these tumors were exploited and led to the improved outcomes seen here (mOS 44.6 mo)
1
1
5
(2/4) HLRCC associated RCC, due to their lack of fumarate hydratase activity, have impaired oxidative phos. and are: 1. Dependent on aerobic glycolysis 2. Sensitive to glucose alterations These tumors also have HIF driven activation of VEGF and EGFR due to ⬆️fumarate
1
0
3
(1/4) Summary Intervention: bevacizumab and erlotinib Cohorts: HLRCC assoc pRCC (n = 43); sporadic papillary RCC (n = 40) Most IMDC intermediate risk HLRCC 📍ORR: 72% 📍CR: 5% 📍mPFS: 21.1 mo 📍mOS: 44.6 mo Sporadic 📍ORR: 35% 📍mPFS 8.9 mo 📍mOS: 18.2 mo Toxicity manageable
1
0
5
Happy to present the latest review in Bladder Cancer by @SandeepGurramMD and @RathiNityam from @NCICCR_UroOnc "Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer" discussing ✅Rationale for devices ✅Devices available ✅Mechanisms ✅Efficacy ✅Safety ✅Future Studies
0
3
5
“What has made our research year so special is the strong sense of community and camaraderie at the NIH.” – Jessica Hsueh, NCI Medical Research Scholar I love to hear feedback like this from NCI trainees. More reflections on a research year in urology: https://t.co/uriH7iz70Q
2
6
23
🚨 Great news in muscle-invasive bladder cancer: NIAGRA phase III trial showed Durvalimab + neoadjuvant chemo improves Event-free and Overall survival 🟢 First CPI in this setting improving outcomes when added to chemo Much awaited news! https://t.co/4pCJhzvMud
#BladderCancer
astrazeneca-us.com
0
0
5
🔵Our group has been working on localized prostate cancer imaging for more than one and a half decades. 🔬🩻We began by optimizing MRI vs. pathology correlation using patient-specific molds. 🔷Over the years, we've developed organ segmentation and lesion detection models in
4
36
131
Excellent work headed by rising 💫 @AntonyMariaB More evidence supporting that where you started off (baseline GFR, preop parenchymal vol) and what you left undisturbed (postop parenchymal vol) are considerably more important than ischemia time.
Preoperative Renal Parenchyma Volume as a Predictor of Kidney Function Following Nephrectomy of Complex Renal Masses https://t.co/4adJKthmrG
@AntonyMariaB @PouriaYazdian @NikhilGopalMD @draditichauras1 @SandeepGurramMD @eb_radnucs @aamalayeri @markballmd
#openscience
0
2
21
Congrats @AntonyMariaB and congrats #AUANews on an awesome editor. Proud, but not surprised. Many more great things to come from this one. #auamatch24
Meet the #AUANews Medical Student Column Editors 🗞️ 🎉 @AntonyMariaB is a 3rd year med student at the University of Connecticut School of Medicine & a former NIH-MRSP student at the NCI Urologic Oncology Branch (mentor @markballmd). She enjoys birdwatching with her family 🐦
1
4
17
Just Released Deepest-ever view of the cosmos from @NASAWebb. The spiked objects are local stars in our own Galaxy. ignore them. Everything else is an entire galaxy. Many distort into arcs, revealing spacetime curvature from the gravity of a galaxy cluster in the image's center.
1K
9K
58K
Exciting News! Hofstra-Northwell Advanced Endoscopy Fellow Monica Passi, M.D. is joining Gastro Health! Dr. Passi will care for patients in Virginia starting in August 2022. #TeamGastroHealth #GIFellow #Gastroenterology #Endoscopy #GITwitter 👏👩⚕️🩺🎉💙
3
2
6
Given dx of HLRCC and fantastic imaging from @aamalayeri & #MarkAhlman @NIHRadiology, we proceeded to radical nephrectomy. Multiple FH-deficient tumors lining the cyst wall. #HLRCC is a different disease: have to dismiss most of the dogma for ccRCC. Cystic dz can still be bad.
Late 60s male, with large cyst x several years. This year we see small mural nodules. Has some comorbidities, a fib, HTN, depressed EF. Family history of RCC. Thoughts on management?
2
12
41
So proud of our former fellow @NCICCR_UroOnc @nciccr_gmb @NCIResearchCtr Dr. @heather_chalfin who gave an outstanding presentation on CTCs and ctDNA biomarkers in Urothelial carcinoma at the #BladderCancer Course at #SUO21 @UroOnc @SUO_YUO @djmcconkey @hopkinskimmel
0
7
26
Congrats, @apolo_andrea! So well deserved. We in the @NCICCR_UroOnc are grateful for our collaborations.
1
1
11
Great thread from @NCIDirector on the history and progress in studying and treating #VHL at @NCICCR_UroOnc. Work would be impossible without the commitment of the > 800 VHL patients we actively treat.
Promising news for people with the rare inherited disorder von Hippel-Lindau (VHL) disease, which can lead to cancer. The @US_FDA recently approved belzutifan, which according to an @NCIResearchCtr study, has shrunk VHL-associated #Tumors. (1/15) https://t.co/CD86UK2zT5
0
2
12
The authors of this study aimed to identify differences in perioperative outcomes, surgical footprints, and complication rates in patients undergoing either open or robotic reoperative partial nephrectomy. https://t.co/oJ50csH8Ez
@SandeepGurramMD @markballmd @NCICCR_UroOnc
0
2
5
@ReemKhondakar @AmerUrological @SandeepGurramMD @PeterPintoMD @NCICCR_UroOnc Congratulations Reem, great job 👍
1
1
2